1
|
Fogaça MBT, Lopes-Luz L, Saavedra DP, de Oliveira NKAB, Jesus Sousa MBD, Perez JDP, de Andrade IA, Crispim GJB, Pinto LDS, Ferreira MRA, Ribeiro BM, Nagata T, Conceição FR, Stefani MMDA, Bührer-Sékula S. Production of antigens expressed in Nicotiana benthamiana plant and Escherichia coli for the SARS-CoV-2 IgG antibody detection by ELISA. J Virol Methods 2024; 329:114969. [PMID: 38834144 DOI: 10.1016/j.jviromet.2024.114969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 05/06/2024] [Accepted: 05/28/2024] [Indexed: 06/06/2024]
Abstract
The recent COVID-19 pandemic disclosed a critical shortage of diagnostic kits worldwide, emphasizing the urgency of utilizing all resources available for the development and production of diagnostic tests. Different heterologous protein expression systems can be employed for antigen production. This study assessed novel SARS-CoV-2 proteins produced by a transient expression system in Nicotiana benthamiana utilizing an infectious clone vector based on pepper ringspot virus (PepRSV). These proteins included the truncated S1-N protein (spike protein N-terminus residues 12-316) and antigen N (nucleocapsid residues 37-402). Two other distinct SARS-CoV-2 antigens expressed in Escherichia coli were evaluated: QCoV9 chimeric antigen protein (spike protein residues 449-711 and nucleocapsid protein residues 160-406) and QCoV7 truncated antigen (nucleocapsid residues 37-402). ELISAs using the four antigens individually and the same panel of samples were performed for the detection of anti-SARS-CoV-2 IgG antibodies. Sensitivity was evaluated using 816 samples from 351 COVID-19 patients hospitalized between 5 and 65 days after symptoms onset; specificity was tested using 195 samples collected before 2018, from domiciliary contacts of leprosy patients. Our findings demonstrated consistent test sensitivity, ranging from 85 % to 88 % with specificity of 97.5 %, regardless of the SARS-CoV2 antigen and the expression system used for production. Our results highlight the potential of plant expression systems as useful alternative platforms to produce recombinant antigens and for the development of diagnostic tests, particularly in resource-constrained settings.
Collapse
Affiliation(s)
- Matheus Bernardes Torres Fogaça
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil; Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, Goiânia, Goiás 74690-900, Brazil
| | - Leonardo Lopes-Luz
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil; Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, Goiânia, Goiás 74690-900, Brazil
| | - Djairo Pastor Saavedra
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil; Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, Goiânia, Goiás 74690-900, Brazil
| | - Nicolle Kathlen Alves Belem de Oliveira
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil
| | - Maria Beatris de Jesus Sousa
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil
| | - Julio Daniel Pacheco Perez
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil
| | - Ikaro Alves de Andrade
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF 70910-900, Brazil
| | - Gildemar José Bezerra Crispim
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF 70910-900, Brazil; Hospital Regional de Santa Maria, Brasília, DF 72502-100, Brazil
| | - Luciano da Silva Pinto
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, CP 354, Pelotas, RS CEP 96160-000, Brazil
| | - Marcos Roberto Alves Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, CP 354, Pelotas, RS CEP 96160-000, Brazil
| | - Bergmann Morais Ribeiro
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF 70910-900, Brazil
| | - Tatsuya Nagata
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF 70910-900, Brazil
| | - Fabricio Rochedo Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, CP 354, Pelotas, RS CEP 96160-000, Brazil
| | - Mariane Martins de Araújo Stefani
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil
| | - Samira Bührer-Sékula
- Laboratório de Produção e Desenvolvimento de Testes Rápidos, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil; Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, Goiânia, Goiás 74690-900, Brazil.
| |
Collapse
|
2
|
Fogaça MBT, Saavedra DP, Lopes-Luz L, Ribeiro BM, da Silva Pinto L, Nagata T, Conceição FR, Stefani MMDA, Buhrer-Sékula S. Development and evaluation of a Lateral flow immunoassay (LFIA) prototype for the detection of IgG anti-SARS-CoV-2 antibodies. Heliyon 2024; 10:e29938. [PMID: 38707409 PMCID: PMC11066624 DOI: 10.1016/j.heliyon.2024.e29938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 03/19/2024] [Accepted: 04/17/2024] [Indexed: 05/07/2024] Open
Abstract
Lateral flow immunoassays (LFIA) for antibody detection represent cost-effective and user-friendly tools for serology assessment. This study evaluated a new LFIA prototype developed with a recombinant chimeric antigen from the spike/S and nucleocapsid/N proteins to detect anti-SARS-CoV-2 IgG antibodies. The evaluation of LFIA sensitivity and specificity used 811 serum samples from 349 hospitalized, SARS-CoV-2 RT-qPCR positive COVID-19 patients, collected at different time points and 193 serum samples from healthy controls. The agreement between ELISA results with the S/N chimeric antigen and LFIA results was calculated. The LFIA prototype for SARS-CoV-2 using the chimeric S/N protein demonstrated 85 % sensitivity on the first week post symptoms onset, reaching 94 % in samples collected at the fourth week of disease. The agreement between LFIA and ELISA with the same antigen was 92.7 %, 0.827 kappa Cohen value (95 % CI [0.765-0.889]). Further improvements are needed to standardize the prototype for whole blood use. The inclusion of the novel chimeric S + N antigen in the COVID-19 IgG antibody LFIA demonstrated optimal agreement with results from a comparable ELISA, highlighting the prototype's potential for accurate large-scale serologic assessments in the field in a rapid and user-friendly format.
Collapse
Affiliation(s)
- Matheus Bernardes Torres Fogaça
- Laboratório de Desenvolvimento e Produção de Testes Rápidos, Centro Multiusuário de Pesquisa de Bioinsumos e Tecnologias em Saúde, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil
- Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, 74690-900, Goiânia, GO, Brazil
| | - Djairo Pastor Saavedra
- Laboratório de Desenvolvimento e Produção de Testes Rápidos, Centro Multiusuário de Pesquisa de Bioinsumos e Tecnologias em Saúde, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil
- Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, 74690-900, Goiânia, GO, Brazil
| | - Leonardo Lopes-Luz
- Laboratório de Desenvolvimento e Produção de Testes Rápidos, Centro Multiusuário de Pesquisa de Bioinsumos e Tecnologias em Saúde, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil
- Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, 74690-900, Goiânia, GO, Brazil
| | - Bergmann Morais Ribeiro
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF, 70910-900, Brazil
| | - Luciano da Silva Pinto
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Laboratório de Imunologia, Aplicada, Universidade Federal de Pelotas, Pelotas, 96010-610, RS, Brazil
| | - Tatsuya Nagata
- Departamento de Biologia Celular, Campus Darcy Ribeiro, Universidade de Brasília, Brasília, DF, 70910-900, Brazil
| | - Fabricio Rochedo Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Laboratório de Imunologia, Aplicada, Universidade Federal de Pelotas, Pelotas, 96010-610, RS, Brazil
| | - Mariane Martins de Araújo Stefani
- Laboratório de Desenvolvimento e Produção de Testes Rápidos, Centro Multiusuário de Pesquisa de Bioinsumos e Tecnologias em Saúde, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil
- Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, 74690-900, Goiânia, GO, Brazil
| | - Samira Buhrer-Sékula
- Laboratório de Desenvolvimento e Produção de Testes Rápidos, Centro Multiusuário de Pesquisa de Bioinsumos e Tecnologias em Saúde, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, GO, 74605-050, Brazil
- Innovation Hub in Point of Care Technologies, Universidade Federal de Goiás-Merck S/A. Alliance, 74690-900, Goiânia, GO, Brazil
| |
Collapse
|
3
|
Pavlidis G, Giannoulis V, Pirounaki M, Lampropoulos IC, Siafi E, Nitsa A, Pavlou E, Xanthaki A, Perlepe G, Fortis SP, Charalambous G, Kampolis CF, Pantazopoulos I. Evaluation of Antibody Kinetics Following COVID-19 Vaccination in Greek SARS-CoV-2 Infected and Naïve Healthcare Workers. J Pers Med 2023; 13:910. [PMID: 37373899 DOI: 10.3390/jpm13060910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 05/26/2023] [Accepted: 05/27/2023] [Indexed: 06/29/2023] Open
Abstract
We investigated the antibody kinetics after vaccination against COVID-19 in healthcare workers of a Greek tertiary hospital. Eight hundred and three subjects were included, of whom 758 (94.4%) received the BNT162b2 vaccine (Pfizer-BioNTech), eight (1%) mRNA-1273 (Moderna), 14 (1.7%) ChAdOx1 (Oxford-AstraZeneca) and 23 (2.9%) Ad26.COV2.S (Janssen). Before the second dose, at 2, 6 and 9 months after the second dose and at 2 and 6 months after the third dose, anti-spike IgG were quantified by the chemiluminescence microparticle immunoassay method. One hundred subjects were infected before vaccination (group A), 335 were infected after receiving at least one vaccine dose (group B), while 368 had never been infected (group C). Group A presented a greater number of hospitalizations and reinfections compared to group B (p < 0.05). By multivariate analysis, younger age was associated with an increased risk of reinfection (odds ratio: 0.956, p = 0.004). All subjects showed the highest antibody titers at 2 months after the second and third dose. Group A showed higher antibody titers pre-second dose, which remained elevated 6 months post-second dose compared to groups B and C (p < 0.05). Pre-vaccine infection leads to rapid development of high antibody titer and a slower decline. Vaccination is associated with fewer hospitalizations and fewer reinfections.
Collapse
Affiliation(s)
- George Pavlidis
- Department of Emergency Medicine, Hippokration General Hospital, 11527 Athens, Greece
| | - Vasileios Giannoulis
- Transfusion and Haemophilia Centre, Hippokration General Hospital, 11527 Athens, Greece
| | - Maria Pirounaki
- Second Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, 11527 Athens, Greece
| | - Ioannis C Lampropoulos
- Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece
| | - Eirini Siafi
- Department of Emergency Medicine, Hippokration General Hospital, 11527 Athens, Greece
| | - Alkippi Nitsa
- Microbiology Department, Hippokration General Hospital, 11527 Athens, Greece
| | - Efthymia Pavlou
- Transfusion and Haemophilia Centre, Hippokration General Hospital, 11527 Athens, Greece
| | - Anna Xanthaki
- Microbiology Department, Hippokration General Hospital, 11527 Athens, Greece
| | - Garyfallia Perlepe
- Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece
| | - Sotirios P Fortis
- Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health and Caring Sciences, University of West Attica, 12243 Egaleo, Greece
| | - George Charalambous
- Department of Emergency Medicine, Hippokration General Hospital, 11527 Athens, Greece
| | - Christos F Kampolis
- Department of Emergency Medicine, Hippokration General Hospital, 11527 Athens, Greece
| | - Ioannis Pantazopoulos
- Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece
- Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece
| |
Collapse
|
4
|
Vidal LEL, Figueira-Mansur J, Jurgilas PB, Argondizzo APC, Pestana CP, Martins FO, da Silva Junior HC, Miguez M, Loureiro BO, Marques CDFS, Trinta KS, da Silva LBR, de Mello MB, da Silva ED, Bastos RC, Esteves G. Process development and characterization of recombinant nucleocapsid protein for its application on COVID-19 diagnosis. Protein Expr Purif 2023; 207:106263. [PMID: 36921810 PMCID: PMC10012136 DOI: 10.1016/j.pep.2023.106263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 03/10/2023] [Indexed: 03/15/2023]
Abstract
COVID-19 pandemic was caused by the severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2). The nucleocapsid (N) protein from Sars-CoV-2 is a highly immunogenic antigen and responsible for genome packing. Serological assays are important tools to detect previous exposure to SARS-CoV-2, complement epidemiological studies, vaccine evaluation and also in COVID-19 surveillance. SARS-CoV-2 N (r2N) protein was produced in Escherichia coli, characterized, and the immunological performance was evaluated by enzyme-linked immunosorbent assay (ELISA) and beads-based array immunoassay. r2N protein oligomers were evidenced when it is associated to nucleic acid. Benzonase treatment reduced host nucleic acid associated to r2N protein, but crosslinking assay still demonstrates the presence of higher-order oligomers. Nevertheless, after RNase treatment the higher-order oligomers reduced, and dimer form increased, suggesting RNA contributes to the oligomer formation. Structural analysis revealed nucleic acid did not interfere with the thermal stability of the recombinant protein. Interestingly, nucleic acid was able to prevent r2N protein aggregation even with increasing temperature while the protein benzonase treated begin aggregation process above 55 °C. In immunological characterization, ELISA performed with 233 serum samples presented a sensitivity of 97.44% (95% Confidence Interval, CI, 91.04%, 99.69%) and a specificity of 98.71% (95% CI, 95.42%, 99.84%) while beads-based array immunoassay carried out with 217 samples showed 100% sensitivity and 98.6% specificity. The results exhibited an excellent immunological performance of r2N protein in serologic assays showing that, even in presence of nucleic acid, it can be used as a component of an immunoassay for the sensitive and specific detection of SARS-CoV-2 antibodies.
Collapse
Affiliation(s)
- Luãnna Elisa Liebscher Vidal
- Macromolecules Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil.
| | - Janaina Figueira-Mansur
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Patrícia Barbosa Jurgilas
- Macromolecules Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Ana Paula Correa Argondizzo
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Cristiane Pinheiro Pestana
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Fernanda Otaviano Martins
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Haroldo Cid da Silva Junior
- Immunological Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Mariana Miguez
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Bernardo Oliveira Loureiro
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Christiane de Fátima Silva Marques
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Karen Soares Trinta
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Leila Botelho Rodrigues da Silva
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Marcelle Bral de Mello
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Edimilson Domingos da Silva
- Diagnostic Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Renata Chagas Bastos
- Macromolecules Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| | - Gabriela Esteves
- Recombinant Technology Laboratory, Institute of Technology in Immunobiologicals (Bio-Manguinhos), Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, 21040-900, Brazil
| |
Collapse
|
5
|
Djaïleb A, Lavallée É, Parker MF, Cayer MP, Desautels F, de Grandmont MJ, Stuible M, Gervais C, Durocher Y, Trottier S, Boudreau D, Masson JF, Brouard D, Pelletier JN. Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. Front Immunol 2023; 13:1052424. [PMID: 36741379 PMCID: PMC9895839 DOI: 10.3389/fimmu.2022.1052424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 12/13/2022] [Indexed: 01/22/2023] Open
Abstract
Introduction Early in the COVID-19 pandemic, reagent availability was not uniform, and infrastructure had to be urgently adapted to undertake COVID-19 surveillance. Methods Before the validation of centralized testing, two enzyme-linked immunosorbent assays (ELISA) were established independently at two decentralized sites using different reagents and instrumentation. We compared the results of these assays to assess the longitudinal humoral response of SARS-CoV-2-positive (i.e., PCR-confirmed), non-hospitalized individuals with mild to moderate symptoms, who had contracted SARSCoV-2 prior to the appearance of variants of concern in Québec, Canada. Results The two assays exhibited a high degree of concordance to identify seropositive individuals, thus validating the robustness of the methods. The results also confirmed that serum immunoglobulins persist ≥ 6 months post-infection among non-hospitalized adults and that the antibodies elicited by infection cross-reacted with the antigens from P.1 (Gamma) and B.1.617.2 (Delta) variants of concern. Discussion Together, these results demonstrate that immune surveillance assays can be rapidly and reliably established when centralized testing is not available or not yet validated, allowing for robust immune surveillance.
Collapse
Affiliation(s)
- Abdelhadi Djaïleb
- Département de Chimie, Université de Montréal, Montréal, QC, Canada
- PROTEO, Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, Québec, QC, Canada
- Centre en Chimie Verte et Catalyse, Université de Montréal, Montréal, QC, Canada
| | - Étienne Lavallée
- Département de Chimie, Université de Montréal, Montréal, QC, Canada
- PROTEO, Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, Québec, QC, Canada
- Centre en Chimie Verte et Catalyse, Université de Montréal, Montréal, QC, Canada
| | - Megan-Faye Parker
- PROTEO, Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, Québec, QC, Canada
- Centre en Chimie Verte et Catalyse, Université de Montréal, Montréal, QC, Canada
- Départment de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
| | | | | | | | - Matthew Stuible
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada
| | - Christian Gervais
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada
| | - Yves Durocher
- PROTEO, Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, Québec, QC, Canada
- Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada
| | - Sylvie Trottier
- Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC, Canada
- Département de Microbiologie-Infectiologie et d’Immunologie, Université Laval, Québec, QC, Canada
| | - Denis Boudreau
- Départment de Chimie, Université Laval, Québec, QC, Canada
- Centre d’Optique, Photonique et Laser, Université Laval, Québec, QC, Canada
| | - Jean-Francois Masson
- Département de Chimie, Université de Montréal, Montréal, QC, Canada
- Centre Québécois sur les Matériaux Fonctionnels, Montréal, QC, Canada
- Centre Interdisciplinaire de Recherche sur le Cerveau et l’Apprentissage, Université de Montréal, Montréal, QC, Canada
| | - Danny Brouard
- Héma‐Québec, Affaires Médicales et Innovation, Québec, QC, Canada
| | - Joelle N. Pelletier
- Département de Chimie, Université de Montréal, Montréal, QC, Canada
- PROTEO, Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, Québec, QC, Canada
- Centre en Chimie Verte et Catalyse, Université de Montréal, Montréal, QC, Canada
- Départment de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada
| |
Collapse
|
6
|
Xue Y, Chen Z, Zhang W, Zhang J. Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics. Bioengineering (Basel) 2022; 9:bioengineering9070291. [PMID: 35877342 PMCID: PMC9312194 DOI: 10.3390/bioengineering9070291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 06/22/2022] [Accepted: 06/27/2022] [Indexed: 12/23/2022] Open
Abstract
Over the past decades, RNA viruses have been threatened people’s health and led to global health emergencies. Significant progress has been made in diagnostic methods and antiviral therapeutics for combating RNA viruses. ELISA and RT-qPCR are reliable methods to detect RNA viruses, but they suffer from time-consuming procedures and limited sensitivities. Vaccines are effective to prevent virus infection and drugs are useful for antiviral treatment, while both need a relatively long research and development cycle. In recent years, CRISPR-based gene editing and modifying tools have been expanded rapidly. In particular, the CRISPR-Cas13 system stands out from the CRISPR-Cas family due to its accurate RNA-targeting ability, which makes it a promising tool for RNA virus diagnosis and therapy. Here, we review the current applications of the CRISPR-Cas13 system against RNA viruses, from diagnostics to therapeutics, and use some medically important RNA viruses such as SARS-CoV-2, dengue virus, and HIV-1 as examples to demonstrate the great potential of the CRISPR-Cas13 system.
Collapse
|
7
|
Lohse S, Sternjakob-Marthaler A, Lagemann P, Schöpe J, Rissland J, Seiwert N, Pfuhl T, Müllendorff A, Kiefer LS, Vogelgesang M, Vella L, Denk K, Vicari J, Zwick A, Lang I, Weber G, Geisel J, Rech J, Schnabel B, Hauptmann G, Holleczek B, Scheiblauer H, Wagenpfeil S, Smola S. German federal-state-wide seroprevalence study of 1 st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. COMMUNICATIONS MEDICINE 2022; 2:52. [PMID: 35603305 PMCID: PMC9117207 DOI: 10.1038/s43856-022-00100-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 03/09/2022] [Indexed: 12/12/2022] Open
Abstract
Background Reliable data on the adult SARS-CoV-2 infection fatality rate in Germany are still scarce. We performed a federal state-wide cross-sectional seroprevalence study named SaarCoPS, that is representative for the adult population including elderly individuals and nursing home residents in the Saarland. Methods Serum was collected from 2940 adults via stationary or mobile teams during the 1st pandemic wave steady state period. We selected an antibody test system with maximal specificity, also excluding seroreversion effects due to a high longitudinal test performance. For the calculations of infection and fatality rates, we accounted for the delays of seroconversion and death after infection. Results Using a highly specific total antibody test detecting anti-SARS-CoV-2 responses over more than 180 days, we estimate an adult infection rate of 1.02% (95% CI: [0.64; 1.44]), an underreporting rate of 2.68-fold (95% CI: [1.68; 3.79]) and infection fatality rates of 2.09% (95% CI: (1.48; 3.32]) or 0.36% (95% CI: [0.25; 0.59]) in all adults including elderly individuals, or adults younger than 70 years, respectively. Conclusion The study highlights the importance of study design and test performance for seroprevalence studies, particularly when seroprevalences are low. Our results provide a valuable baseline for evaluation of future pandemic dynamics and impact of public health measures on virus spread and human health in comparison to neighbouring countries such as Luxembourg or France.
Collapse
Affiliation(s)
- Stefan Lohse
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | | | - Paul Lagemann
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Jakob Schöpe
- Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Medical Center, 66421 Homburg, Germany
| | - Jürgen Rissland
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Nastasja Seiwert
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Thorsten Pfuhl
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Alana Müllendorff
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Laurent S Kiefer
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Markus Vogelgesang
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Luca Vella
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Katharina Denk
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Julia Vicari
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Anabel Zwick
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Isabelle Lang
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany
| | - Gero Weber
- Physical Geography and Environmental Research, Saarland University, 66125 Saarbrücken, Germany
| | - Jürgen Geisel
- Central Laboratory, Saarland University Hospital, 66421 Homburg, Germany
| | - Jörg Rech
- Ministry of Health, Social Affairs, Women and the Family, 66119 Saarbrücken, Germany
| | - Bernd Schnabel
- Ministry of Health, Social Affairs, Women and the Family, 66119 Saarbrücken, Germany
| | - Gunter Hauptmann
- Kassenärztliche Vereinigung Saarland, 66113 Saarbrücken, Germany
| | - Bernd Holleczek
- Ministry of Health, Social Affairs, Women and the Family, 66119 Saarbrücken, Germany.,Saarland Cancer Registry, 66117 Saarbrücken, Germany
| | | | - Stefan Wagenpfeil
- Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Medical Center, 66421 Homburg, Germany
| | - Sigrun Smola
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany.,Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University Campus, 66123 Saarbrücken, Germany
| |
Collapse
|
8
|
Bandeira CCS, Madureira KCR, Rossi MB, Gallo JF, da Silva APMA, Torres VL, de Lima VA, Júnior NK, Almeida JD, Zerbinati RM, Braz-Silva PH, Lindoso JAL, da Silva Martinho H. Micro-Fourier-transform infrared reflectance spectroscopy as tool for probing IgG glycosylation in COVID-19 patients. Sci Rep 2022; 12:4269. [PMID: 35277543 PMCID: PMC8914452 DOI: 10.1038/s41598-022-08156-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 02/23/2022] [Indexed: 12/13/2022] Open
Abstract
It has been reported that patients diagnosed with COVID-19 become critically ill primarily around the time of activation of the adaptive immune response. However the role of antibodies in the worsening of disease is not obvious. Higher titers of anti-spike immunoglobulin IgG1 associated with low fucosylation of the antibody Fc tail have been associated to excessive inflammatory response. In contrast it has been also reported that NP-, S-, RBD- specific IgA, IgG, and IgM are not associated with SARS-CoV-2 viral load, indicating that there is no obvious correlation between antibody response and viral antigen detection. In the present work the micro-Fourier-transform infrared reflectance spectroscopy (micro-FTIR) was employed to investigate blood serum samples of healthy and COVID-19-ill (mild or oligosymptomatic) individuals (82 healthcare workers volunteers in “Instituto de Infectologia Emilio Ribas”, São Paulo, Brazil). The molecular-level-sensitive, multiplexing quantitative and qualitative FTIR data probed on 1 µL of dried biofluid was compared to signal-to-cutoff index of chemiluminescent immunoassays CLIA and ELISA (IgG antibodies against SARS-CoV-2). Our main result indicated that 1702–1785 \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\hbox {cm}^{-1}$$\end{document}cm-1 spectral window (carbonyl C=O vibration) is a spectral marker of the degree of IgG glycosylation, allowing to probe distinctive sub-populations of COVID-19 patients, depending on their degree of severity. The specificity was 87.5 % while the detection rate of true positive was 100%. The computed area under the receiver operating curve was equivalent to CLIA, ELISA and other ATR-FTIR methods (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$>0.85$$\end{document}>0.85). In summary, overall discrimination of healthy and COVID-19 individuals and severity prediction as well could be potentially implemented using micro-FTIR reflectance spectroscopy on blood serum samples. Considering the minimal and reagent-free sample preparation procedures combined to fast (few minutes) outcome of FTIR we can state that this technology is suitable for fast screening of immune response of individuals with COVID-19. It would be an important tool in prospective studies, helping investigate the physiology of the asymptomatic, oligosymptomatic, or severe individuals and measure the extension of infection dissemination in patients.
Collapse
Affiliation(s)
| | | | - Meire Bocoli Rossi
- Instituto de Infectologia Emilio Ribas, São Paulo, Sp, 01246-900, Brazil
| | | | | | | | - Vinicius Alves de Lima
- Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil
| | - Norival Kesper Júnior
- Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil
| | - Janete Dias Almeida
- Departamento de Biociências e Diagnêstico, Instituto de Ciência e Tecnologia, Universidade Estadual Paulista, São José dos Campos, SP, 12245-000, Brazil
| | - Rodrigo Melim Zerbinati
- Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil
| | - Paulo Henrique Braz-Silva
- Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil.,Faculdade de Odontologia Departamento de Estomatologia, Universidade de São Paulo, São Paulo, SP, 05508-000, Brazil
| | - José Angelo Lauletta Lindoso
- Instituto de Infectologia Emilio Ribas, São Paulo, Sp, 01246-900, Brazil.,Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, SP, 05403-000, Brazil.,Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, 01255-090, Brazil
| | | |
Collapse
|
9
|
Romero-Ibarguengoitia ME, Rivera-Salinas D, Hernández-Ruíz YG, Armendariz-Vázquez AG, González-Cantú A, Barco-Flores IA, González-Facio R, Montelongo-Cruz LP, Del Rio-Parra GF, Garza-Herrera MR, Leal-Meléndez JA, Sanz-Sánchez MÁ. Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel. PLoS One 2022; 17:e0263942. [PMID: 35235587 PMCID: PMC8890651 DOI: 10.1371/journal.pone.0263942] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 01/28/2022] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Vaccination is our main strategy to control SARS-CoV-2 infection. Given the decrease in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months after the second BNT162b2 dose, healthcare workers received a third booster six months after completing the original protocol. This study aimed to analyze the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and the safety of the third dose. MATERIAL AND METHODS A prospective longitudinal cohort study included healthcare workers who received a third booster six months after completing the BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the completed protocol, 1-7 days following the third dose, and 21-28 days after booster administration. RESULTS The cohort comprised 168 participants aged 41(10) years old, 67% of whom were female. The third dose was associated with an increase in quantitative antibody titers, regardless of previous SARS-CoV-2 history. In cases with a negative SARS-CoV-2 history, the median (IQR) antibody titer values increased from 379 (645.4) to 2960 (2010) AU/ml, whereas in cases with a positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080) AU/ml (p<0.001). The third dose caused a lower number of total (local and systemic) adverse events following immunization (AEFI) compared with the first two vaccines. However, in terms of specific symptoms such as fatigue, myalgia, arthralgia, fever, and adenopathy, the proportion was higher in comparison with the first and second doses (p<0.05). The most common AEFI after the third BNT162b2 vaccine was pain at the injection site (n = 82, 84.5%), followed by fatigue (n = 45, 46.4%) of mild severity (n = 36, 37.1%). CONCLUSION The third dose applied six months after the original BNT162b2 regimen increased the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated and caused no severe AEFI.
Collapse
Affiliation(s)
- Maria Elena Romero-Ibarguengoitia
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Diego Rivera-Salinas
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Yodira Guadalupe Hernández-Ruíz
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Ana Gabriela Armendariz-Vázquez
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Arnulfo González-Cantú
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | | | - Rosalinda González-Facio
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
| | - Laura Patricia Montelongo-Cruz
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Gerardo Francisco Del Rio-Parra
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Mauricio René Garza-Herrera
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Jessica Andrea Leal-Meléndez
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| | - Miguel Ángel Sanz-Sánchez
- Department of Investigation, Hospital Clínica Nova de Monterrey, San Nicolás de los Garza, Nuevo León, Mexico
- Vice-Presidency of Academic Affairs in Health Sciences, School of Medicine, Universidad de Monterrey, San Pedro Garza García, Nuevo León, Mexico
| |
Collapse
|